{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:52:00Z","timestamp":1791845520117,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","award":["21\/2551-0000065-1"],"award-info":[{"award-number":["21\/2551-0000065-1"]}],"id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11095-023-03544-7","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T20:35:25Z","timestamp":1686256525000},"page":"1777-1787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Population Pharmacokinetic Model of Methotrexate in Brazilian Pediatric Patients with Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"40","author":[{"given":"Pricilla","family":"de Oliveira Henz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Valle","family":"Pinhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauro Jos\u00e9","family":"Gregianin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoela","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Curra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibiana Verlindo","family":"de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9227-2991","authenticated-orcid":false,"given":"Teresa","family":"Dalla Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"issue":"1","key":"3544_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","volume":"119","author":"GM Dores","year":"2012","unstructured":"Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001\u20132007. Blood. 2012;119(1):34\u201343. https:\/\/doi.org\/10.1182\/blood-2011-04-347872.","journal-title":"Blood"},{"issue":"3","key":"3544_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jphotobiol.2011.04.005","volume":"104","author":"S Chibber","year":"2011","unstructured":"Chibber S, Hassan I, Farhan M, Naseem I. In vitro pro-oxidant action of Methotrexate in presence of white light. J Photochem Photobiol B. 2011;104(3):387\u201393. https:\/\/doi.org\/10.1016\/j.jphotobiol.2011.04.005.","journal-title":"J Photochem Photobiol B"},{"issue":"71 Suppl 1","key":"3544_CR3","first-page":"S5","volume":"2013","author":"ES Chan","year":"2013","unstructured":"Chan ES, Cronstein BN. Mechanisms of action of methotrexate. Bull Hosp Jt Dis. 2013;2013(71 Suppl 1):S5\u20138.","journal-title":"Bull Hosp Jt Dis"},{"key":"3544_CR4","doi-asserted-by":"crossref","unstructured":"Gao B, Klumpen H-J, Gurney H. Defining the Starting Dose: Should It Be mg\/kg, mg\/m2, or Fixed? In: Rudek MA, editors. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. 2 ed. Baltimore, USA: Humana Press; 2014. p. 69\u201387.","DOI":"10.1007\/978-1-4614-9135-4_4"},{"issue":"1","key":"3544_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::aid-cncr2820410108>3.0.co;2-i","volume":"41","author":"WA Bleyer","year":"1978","unstructured":"Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41(1):36\u201351. https:\/\/doi.org\/10.1002\/1097-0142(197801)41:1%3c36::aid-cncr2820410108%3e3.0.co;2-i.","journal-title":"Cancer"},{"key":"3544_CR6","doi-asserted-by":"publisher","unstructured":"Gaies E, Jebabli N. Methotrexate side effects: Review article. J Drug Metab Toxicol. 2012;3(4). https:\/\/doi.org\/10.4172\/2157-7609.1000125.","DOI":"10.4172\/2157-7609.1000125."},{"issue":"2","key":"3544_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4155\/ipk-2016-0022","volume":"2","author":"D Lev\u00eaque","year":"2017","unstructured":"Lev\u00eaque D, Becker G, Toussaint E, Fornecker L-M, Paillard C. Clinical pharmacokinetics of methotrexate in oncology. Int J Pharmacokinet. 2017;2(2):137\u201347. https:\/\/doi.org\/10.4155\/ipk-2016-0022.","journal-title":"Int J Pharmacokinet"},{"key":"3544_CR8","doi-asserted-by":"publisher","unstructured":"Campbell M, Kiss C, Zimmermann M, et al. Childhood acute lymphoblastic leukemia: Results of the randomized acute lymphoblastic leukemia intercontinental-Berlin-Frankfurt-M\u00fcnster 2009 Trial. J Clin Oncol. 2023;JCO2201760. https:\/\/doi.org\/10.1200\/JCO.22.01760.","DOI":"10.1200\/JCO.22.01760"},{"key":"3544_CR9","doi-asserted-by":"publisher","unstructured":"Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014;32(3):174\u2013184. https:\/\/doi.org\/10.1200\/JCO.2013.48.6522.","DOI":"10.1200\/JCO.2013.48.6522"},{"key":"3544_CR10","doi-asserted-by":"publisher","unstructured":"Brandalise SR, Pinheiro VR, Aguiar SS, et al. Benefits of the intermittent use of 6 mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99. J Clin Oncol. 2010;28(11):1911\u20131918. https:\/\/doi.org\/10.1200\/JCO.2009.25.6115.","DOI":"10.1200\/JCO.2009.25.6115"},{"key":"3544_CR11","doi-asserted-by":"publisher","unstructured":"Pieters R, De Lorenzo P, Ancliffe P, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study. J Clin\u00a0Oncol. 2019;37(25):2246\u20132256. https:\/\/doi.org\/10.1200\/JCO.19.00261.","DOI":"10.1200\/JCO.19.00261"},{"key":"3544_CR12","doi-asserted-by":"publisher","unstructured":"Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia. 2000;14(12):2257-2266. https:\/\/doi.org\/10.1038\/sj.leu.2401960.","DOI":"10.1038\/sj.leu.2401960"},{"issue":"6","key":"3544_CR13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.19.01086","volume":"38","author":"KW Maloney","year":"2020","unstructured":"Maloney KW, Devidas M, Wang C, et al. Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: results of Children\u2019s Oncology Group Trial AALL0331. J Clin Oncol. 2020;38(6):602\u201312. https:\/\/doi.org\/10.1200\/JCO.19.01086.","journal-title":"J Clin Oncol"},{"key":"3544_CR14","unstructured":"Evans W, Schentag JJ, Jusko WJ. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3 ed. Vancouver: Applied Therapeutics; 1992. p. 617\u2013636."},{"key":"3544_CR15","unstructured":"Winter ME. Basic Clinical Pharmacokinetics. 3 ed. Vancouver: Applied Therapeutics; 1994. p. 266\u2013288."},{"issue":"12","key":"3544_CR16","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2165\/00003088-200645120-00007","volume":"45","author":"D Aumente","year":"2006","unstructured":"Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, Garc\u00eda MJ. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006;45(12):1227\u201338. https:\/\/doi.org\/10.2165\/00003088-200645120-00007.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"3544_CR17","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40262-018-00734-0","volume":"58","author":"RJ Beechinor","year":"2019","unstructured":"Beechinor RJ, Thompson PA, Hwang MF, et al. The population pharmacokinetics of high-dose methotrexate in infants with acute lymphoblastic leukemia highlight the need for bedside individualized dose adjustment: a report from the Children\u2019s Oncology Group. Clin Pharmacokinet. 2019;58(7):899\u2013910. https:\/\/doi.org\/10.1007\/s40262-018-00734-0.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"3544_CR18","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3324\/haematol.2009.019778","volume":"95","author":"TD Buitenkamp","year":"2010","unstructured":"Buitenkamp TD, Math\u00f4t RA, de Haas V, Pieters R, Zwaan CM. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica. 2010;95(7):1106\u201313. https:\/\/doi.org\/10.3324\/haematol.2009.019778.","journal-title":"Haematologica"},{"issue":"4","key":"3544_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/jcph.1349","volume":"59","author":"KH Hui","year":"2019","unstructured":"Hui KH, Chu HM, Fong PS, Cheng WTF, Lam TN. Population pharmacokinetic study and individual dose adjustments of high-dose methotrexate in chinese pediatric patients with acute lymphoblastic leukemia or osteosarcoma. J Clin Pharmacol. 2019;59(4):566\u201377. https:\/\/doi.org\/10.1002\/jcph.1349.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"3544_CR20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","volume":"67","author":"B FaganelKotnik","year":"2011","unstructured":"FaganelKotnik B, Grabnar I, Bohanec Grabar P, Dol\u017ean V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol. 2011;67(10):993\u20131006. https:\/\/doi.org\/10.1007\/s00228-011-1046-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3544_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00280-019-03977-1","volume":"85","author":"SE Medellin-Garibay","year":"2020","unstructured":"Medellin-Garibay SE, Hern\u00e1ndez-Villa N, Correa-Gonz\u00e1lez LC, et al. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2020;85(1):21\u201331. https:\/\/doi.org\/10.1007\/s00280-019-03977-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"3544_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1472-8206.1999.tb00366.x","volume":"13","author":"F Odoul","year":"1999","unstructured":"Odoul F, Le Guellec C, Lamagn\u00e8re JP, et al. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. Fundam Clin Pharmacol. 1999;13(5):595\u2013604. https:\/\/doi.org\/10.1111\/j.1472-8206.1999.tb00366.x.","journal-title":"Fundam Clin Pharmacol"},{"key":"3544_CR23","doi-asserted-by":"publisher","unstructured":"Plard C, Bressolle F, Fakhoury M, et al. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia [published correction appears in Cancer Chemother Pharmacol. 2007 Sep;60(4):621. Piard, Christine [corrected to Plard, Christine]]. Cancer Chemother Pharmacol. 2007;60(4):609\u2013620. https:\/\/doi.org\/10.1007\/s00280-006-0394-3.","DOI":"10.1007\/s00280-006-0394-3."},{"issue":"1","key":"3544_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/cts.12879","volume":"14","author":"RR Schulte","year":"2021","unstructured":"Schulte RR, Choi L, Utreja N, Van Driest SL, Stein CM, Ho RH. Effect of SLCO1B1 polymorphisms on high-dose methotrexate clearance in children and young adults with leukemia and lymphoblastic lymphoma. Clin Transl Sci. 2021;14(1):343\u201353. https:\/\/doi.org\/10.1111\/cts.12879.","journal-title":"Clin Transl Sci"},{"issue":"11","key":"3544_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00431-006-0188-y","volume":"165","author":"BJ Anderson","year":"2006","unstructured":"Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr. 2006;165(11):741\u20136. https:\/\/doi.org\/10.1007\/s00431-006-0188-y.","journal-title":"Eur J Pediatr"},{"key":"3544_CR26","doi-asserted-by":"crossref","unstructured":"Tagen M, Stewart CF. Clinical Pharmacology in Pediatrics. In: Teicher BA, Rudek MA, Chau CH, Figg WD, Mcleod HL, editors. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. 2 ed. New York: Humana Press; 2014. 625 p.","DOI":"10.1007\/978-1-4614-9135-4_31"},{"issue":"8","key":"3544_CR27","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.ejca.2008.12.004","volume":"45","author":"E De Mattia","year":"2009","unstructured":"De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer. 2009;45(8):1333\u201351. https:\/\/doi.org\/10.1016\/j.ejca.2008.12.004.","journal-title":"Eur J Cancer"},{"issue":"12","key":"3544_CR28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/jcph.1252","volume":"58","author":"G Lui","year":"2018","unstructured":"Lui G, Treluyer JM, Fresneau B, et al. A pharmacokinetic and pharmacogenetic analysis of osteosarcoma patients treated with high-dose methotrexate: data from the OS2006\/Sarcoma-09 Trial. J Clin Pharmacol. 2018;58(12):1541\u20139. https:\/\/doi.org\/10.1002\/jcph.1252.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"3544_CR29","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.clinthera.2012.06.022","volume":"34","author":"IW Kim","year":"2012","unstructured":"Kim IW, Yun HY, Choi B, et al. ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis. Clin Ther. 2012;34(8):1816\u201326. https:\/\/doi.org\/10.1016\/j.clinthera.2012.06.022.","journal-title":"Clin Ther"},{"issue":"2","key":"3544_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/106002809202600219","volume":"26","author":"ML Frenia","year":"1992","unstructured":"Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother. 1992;26(2):234\u20137. https:\/\/doi.org\/10.1177\/106002809202600219.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"3544_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5414\/CP203604","volume":"58","author":"R Inose","year":"2020","unstructured":"Inose R, Hashimoto N, Hosomi K, Yokoyama S, Takada M. Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2020;58(3):131\u20138. https:\/\/doi.org\/10.5414\/CP203604.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9","key":"3544_CR32","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1345\/aph.19094","volume":"34","author":"B Beorlegui","year":"2000","unstructured":"Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrases\u00famega L, Gir\u00e1ldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000;34(9):1024\u20137. https:\/\/doi.org\/10.1345\/aph.19094.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"3544_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1620\/tjem.150.481","volume":"150","author":"S Kitaoka","year":"1986","unstructured":"Kitaoka S, Terasawa M, Goto E, Miyaji T, Tsuchiya S, Konno T. Trimethoprim interference in methotrexate assay by an enzyme inhibition assay kit. Tohoku J Exp Med. 1986;150(4):481\u20132. https:\/\/doi.org\/10.1620\/tjem.150.481.","journal-title":"Tohoku J Exp Med"},{"issue":"3","key":"3544_CR34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.12886","volume":"166","author":"K Csordas","year":"2014","unstructured":"Csordas K, Lautner-Csorba O, Semsei AF, et al. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2014;166(3):410\u201320. https:\/\/doi.org\/10.1111\/bjh.12886.","journal-title":"Br J Haematol"},{"issue":"2","key":"3544_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00280-014-2507-8","volume":"74","author":"SM Wang","year":"2014","unstructured":"Wang SM, Sun LL, Zeng WX, Wu WS, Zhang GL. Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2014;74(2):283\u20139. https:\/\/doi.org\/10.1007\/s00280-014-2507-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3544_CR36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10038-006-0096-z","volume":"52","author":"H Imanishi","year":"2007","unstructured":"Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52(2):166\u201371. https:\/\/doi.org\/10.1007\/s10038-006-0096-z.","journal-title":"J Hum Genet"},{"issue":"4","key":"3544_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/DMA-2011-0884","volume":"32","author":"MA Chiabai","year":"2012","unstructured":"Chiabai MA, Lins TC, Pogue R, Pereira RW. Population analysis of pharmacogenetic polymorphisms related to acute lymphoblastic leukemia drug treatment. Dis Markers. 2012;32(4):247\u201353. https:\/\/doi.org\/10.3233\/DMA-2011-0884.","journal-title":"Dis Markers"},{"issue":"6","key":"3544_CR38","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41397-018-0047-z","volume":"18","author":"A Giletti","year":"2018","unstructured":"Giletti A, Esperon P. Genetic markers in methotrexate treatments. Pharmacogenomics J. 2018;18(6):689\u2013703. https:\/\/doi.org\/10.1038\/s41397-018-0047-z.","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"3544_CR39","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/tpj.2012.37","volume":"13","author":"N Simon","year":"2013","unstructured":"Simon N, Marsot A, Villard E, et al. Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenomics J. 2013;13(6):507\u201313. https:\/\/doi.org\/10.1038\/tpj.2012.37.","journal-title":"Pharmacogenomics J"},{"key":"3544_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/9781118784860","volume-title":"Introduction to population pharmacokinetic\/pharmacodynamic analysis with nonlinear mixed effects models","author":"JS Owen","year":"2014","unstructured":"Owen JS, Fiedler-Kelly J. Introduction to population pharmacokinetic\/pharmacodynamic analysis with nonlinear mixed effects models. Hoboken, NJ: Wiley; 2014."},{"issue":"3","key":"3544_CR41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629\u201337. https:\/\/doi.org\/10.1681\/ASN.2008030287.","journal-title":"J Am Soc Nephrol"},{"key":"3544_CR42","unstructured":"Body mass inder-for-age (BMI-for-age). World Health Organization. https:\/\/www.who.int\/toolkits\/child-growth-standards\/standards\/body-mass-index-for-age-bmi-for-age. Accessed 20 Oct 2021."},{"issue":"1","key":"3544_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.106.110379","volume":"320","author":"AA El-Sheikh","year":"2007","unstructured":"El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2\/ABCC2- and MRP4\/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007;320(1):229\u201335. https:\/\/doi.org\/10.1124\/jpet.106.110379.","journal-title":"J Pharmacol Exp Ther"},{"key":"3544_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3899\/jrheum.120345","volume":"90","author":"AN Colebatch","year":"2012","unstructured":"Colebatch AN, Marks JL, van der Heijde DM, Edwards CJ. Safety of nonsteroidal antiinflammatory drugs and\/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012;90:62\u201373. https:\/\/doi.org\/10.3899\/jrheum.120345.","journal-title":"J Rheumatol Suppl"},{"issue":"3","key":"3544_CR45","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/1078155215594417","volume":"22","author":"T Wiczer","year":"2016","unstructured":"Wiczer T, Dotson E, Tuten A, Phillips G, Maddocks K. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract. 2016;22(3):430\u20136. https:\/\/doi.org\/10.1177\/1078155215594417.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"3544_CR46","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1634\/theoncologist.2011-0431","volume":"17","author":"S Bezabeh","year":"2012","unstructured":"Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012;17(4):550\u20134. https:\/\/doi.org\/10.1634\/theoncologist.2011-0431.","journal-title":"Oncologist"},{"key":"3544_CR47","doi-asserted-by":"publisher","unstructured":"Ma SN, Zaman Huri H, Yahya F. Drug-related problems in patients with rheumatoid arthritis. Ther Clin Risk Manag. 2019;15:505\u2013524. Published 2019 Mar 21. https:\/\/doi.org\/10.2147\/TCRM.S194921.","DOI":"10.2147\/TCRM.S194921."},{"issue":"1","key":"3544_CR48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1590\/S0482-50042011000100003","volume":"51","author":"F Bagatini","year":"2011","unstructured":"Bagatini F, Blatt CR, Maliska G, et al. Potential drug interactions in patients with rheumatoid arthritis. Rev Bras Reumatol. 2011;51(1):20\u201339.","journal-title":"Rev Bras Reumatol"},{"key":"3544_CR49","unstructured":"Johansson \u00c5M. Methodology for handling missing data in nonlinear mixed effects modelling. In: Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 189. Uppsala: Acta Universitatis Upsaliensis; 2014. p. 75."},{"issue":"1","key":"3544_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3978\/j.issn.2305-5839.2015.12.38","volume":"4","author":"Z Zhang","year":"2016","unstructured":"Zhang Z. Missing data imputation: focusing on single imputation. Ann Transl Med. 2016;4(1):9. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.12.38.","journal-title":"Ann Transl Med"},{"key":"3544_CR51","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1128\/AAC.02654-15","volume":"60","author":"C Bloomfield","year":"2016","unstructured":"Bloomfield C, et al. Assessing predictive performance of published population pharmacokinetic models of intravenous tobramycin in pediatric patients. Antimicrob Agents Chemother. 2016;60:3407\u201314. https:\/\/doi.org\/10.1128\/AAC.02654-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"3544_CR52","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/pharmaceutics15020569","volume":"15","author":"S Wang","year":"2023","unstructured":"Wang S, et al. External evaluation of population pharmacokinetic models of methotrexate for model-informed precision dosing in pediatric patients with acute lymphoid leukemia. Pharmaceutics. 2023;15:569. https:\/\/doi.org\/10.3390\/pharmaceutics15020569.","journal-title":"Pharmaceutics"},{"issue":"6","key":"3544_CR53","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/cncr.32606","volume":"126","author":"CR Rausch","year":"2020","unstructured":"Rausch CR, Jabbour EJ, Kantarjian HM, Kadia TM. Optimizing the use of the hyperCVAD regimen: clinical vignettes and practical management. Cancer. 2020;126(6):1152\u201360. https:\/\/doi.org\/10.1002\/cncr.32606.","journal-title":"Cancer"},{"key":"3544_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejca.2021.03.034","volume":"151","author":"C Eckert","year":"2021","unstructured":"Eckert C, Parker C, Moorman AV, Irving JA, Kirschner-Schwabe R, Groeneveld-Krentz S, R\u00e9v\u00e9sz T, Hoogerbrugge P, Hancock J, Sutton R, Henze G, Chen-Santel C, Attarbaschi A, Bourquin JP, Sramkova L, Zimmermann M, Krishnan S, von Stackelberg A, Saha V. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021;151:175\u201389. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.034.","journal-title":"Eur J Cancer"},{"issue":"1\u20132","key":"3544_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.mrgentox.2011.10.009","volume":"741","author":"M Stanczyk","year":"2012","unstructured":"Stanczyk M, Sliwinski T, Trelinska J, Cuchra M, Markiewicz L, Dziki L, Bieniek A, Bielecka-Kowalska A, Kowalski M, Pastorczak A, Szemraj J, Mlynarski W, Majsterek I. Role of base-excision repair in the treatment of childhood acute lymphoblastic leukaemia with 6-mercaptopurine and high doses of methotrexate. Mutat Res. 2012;741(1\u20132):13\u201321. https:\/\/doi.org\/10.1016\/j.mrgentox.2011.10.009.","journal-title":"Mutat Res"},{"issue":"2","key":"3544_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/FTD.0000000000000381","volume":"39","author":"JB Woillard","year":"2017","unstructured":"Woillard JB, Debord J, Benz-de-Bretagne I, et al. A time-dependent model describes methotrexate elimination and supports dynamic modification of MRP2\/ABCC2 activity. Ther Drug Monit. 2017;39(2):145\u201356. https:\/\/doi.org\/10.1097\/FTD.0000000000000381.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"3544_CR57","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.26355\/eurrev_201901_17009","volume":"23","author":"S Triarico","year":"2019","unstructured":"Triarico S, Rinninella E, Cintoni M, Capozza MA, Mastrangelo S, Mele MC, Ruggiero A. Impact of malnutrition on survival and infections among pediatric patients with cancer: a retrospective study. Eur Rev Med Pharmacol Sci. 2019;23(3):1165\u201375. https:\/\/doi.org\/10.26355\/eurrev_201901_17009.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3544_CR58","doi-asserted-by":"publisher","unstructured":"Mendes MVC, G\u00f3es ACF, Brain FRM. Children and Adolescents in Cancer Treatment: an Analysis of the Vision of Postponing the Beginning or Interruption of School Education. Revista Brasileira de Cancerologia 2018; 64(3): 301\u2013308. https:\/\/doi.org\/10.32635\/2176-9745.RBC.2018v64n3.27.","DOI":"10.32635\/2176-9745.RBC.2018v64n3.27."},{"key":"3544_CR59","doi-asserted-by":"publisher","unstructured":"Bedoui Y, Guillot X, S\u00e9lambarom J, et al. Methotrexate an Old Drug with New Tricks. Int J Mol Sci. 2019;20(20):5023. Published 2019 Oct 10. https:\/\/doi.org\/10.3390\/ijms20205023.","DOI":"10.3390\/ijms20205023."},{"issue":"4","key":"3544_CR60","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1046\/j.1365-2125.1998.t01-1-00790.x","volume":"46","author":"C Godfrey","year":"1998","unstructured":"Godfrey C, Sweeney K, Miller K, Hamilton R, Kremer J. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol. 1998;46(4):369\u201376. https:\/\/doi.org\/10.1046\/j.1365-2125.1998.t01-1-00790.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3544_CR61","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bcp.14160","volume":"86","author":"JC Panetta","year":"2020","unstructured":"Panetta JC, Roberts JK, Huang J, et al. Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. Br J Clin Pharmacol. 2020;86(2):362\u201371. https:\/\/doi.org\/10.1111\/bcp.14160.","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"3544_CR62","first-page":"153","volume":"37","author":"K Makris","year":"2016","unstructured":"Makris K, Spanou L. Acute kidney injury: diagnostic approaches and controversies. Clin Biochem Rev. 2016;37(4):153\u201375.","journal-title":"Clin Biochem Rev."},{"issue":"2","key":"3544_CR63","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ckj\/sfs013","volume":"5","author":"S Uchino","year":"2012","unstructured":"Uchino S, Bellomo R, Goldsmith D. The meaning of the blood urea nitrogen\/creatinine ratio in acute kidney injury. Clin Kidney J. 2012;5(2):187\u201391. https:\/\/doi.org\/10.1093\/ckj\/sfs013.","journal-title":"Clin Kidney J."},{"key":"3544_CR64","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.2147\/CMAR.S172117","volume":"10","author":"C Traivaree","year":"2018","unstructured":"Traivaree C, Likasitthananon N, Monsereenusorn C, Rujkijyanont P. The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients. Cancer Manag Res. 2018;10:4471\u20138. https:\/\/doi.org\/10.2147\/CMAR.S172117.","journal-title":"Cancer Manag Res."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-023-03544-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-023-03544-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-023-03544-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T04:11:11Z","timestamp":1691727071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-023-03544-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3544"],"URL":"https:\/\/doi.org\/10.1007\/s11095-023-03544-7","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}